FDA Approves Datopotamab Deruxtecan-dlnk for Unresectable or Metastatic, Hormone Receptor-positive, HER2-negative Breast Cancer By Ogkologos - February 27, 2025 499 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the TROPION-Breast01 study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR ΣΑΡΚΩΜΑ February 7, 2019 Strangers Buy Boy Stuffed Animals For His Birthday When His Mom... August 25, 2021 Tackling under-representation of Black data scientists in cancer research November 7, 2022 Safety, Tolerability and Antitumour Activity of Lorlatinib in Patients with ALK-Driven... April 7, 2023 Load more HOT NEWS Study presents an AI-guided approach to target cancer antigens This Company Is Turning Scrap Wood Into 10,000+ Guitars For Sick... Trial Should Change Care for AIDS-Related Kaposi Sarcoma in Sub-Saharan Africa FDA Approves Abatacept for Prophylaxis of Acute Graft Versus Host Disease
